Molecular testing to optimize therapeutic decision making in advanced colorectal cancer

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a leading cause of cancer death in the United States. In recent years, therapeutic advances have prolonged the survival of patients with advanced disease. Along with the addition of new treatments, an increasing body of literature explores the potential benefit of using molecular testing to define tumor, circulating, or host biomarkers of benefit to specific treatment strategies. At present, testing for specific mutations in exons 2, 3, and 4 of KRAS and NRAS has become accepted practice to select patients for treatment with epidermal growth factor receptor (EGFR)-targeted agents. Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. Nonetheless, molecular markers to predict response and toxicity of cytotoxic therapy are evolving. While the development of selection biomarkers for antiangiogenic treatments has not proved fruitful to date, improved development strategies and novel targeted agents are anticipated to revolutionize the approach to treatment of advanced CRC in the near future. This review summarizes currently available data to select treatment strategies in patients with advanced CRC.

Original languageEnglish (US)
Pages (from-to)S11-S20
JournalJournal of Gastrointestinal Oncology
Volume7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Colorectal Neoplasms
Decision Making
irinotecan
Therapeutics
Biomarkers
Glucuronosyltransferase
Mutation
Uridine Diphosphate
Epidermal Growth Factor Receptor
Cause of Death
Exons
Neoplasms
Survival

Keywords

  • Biomarker
  • BRAF
  • Colorectal cancer (CRC)
  • RAS

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. / Semrad, Thomas; Kim, Edward.

In: Journal of Gastrointestinal Oncology, Vol. 7, 01.04.2016, p. S11-S20.

Research output: Contribution to journalReview article

@article{572d828408814d33b5e40a68453f5075,
title = "Molecular testing to optimize therapeutic decision making in advanced colorectal cancer",
abstract = "Colorectal cancer (CRC) is a leading cause of cancer death in the United States. In recent years, therapeutic advances have prolonged the survival of patients with advanced disease. Along with the addition of new treatments, an increasing body of literature explores the potential benefit of using molecular testing to define tumor, circulating, or host biomarkers of benefit to specific treatment strategies. At present, testing for specific mutations in exons 2, 3, and 4 of KRAS and NRAS has become accepted practice to select patients for treatment with epidermal growth factor receptor (EGFR)-targeted agents. Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. Nonetheless, molecular markers to predict response and toxicity of cytotoxic therapy are evolving. While the development of selection biomarkers for antiangiogenic treatments has not proved fruitful to date, improved development strategies and novel targeted agents are anticipated to revolutionize the approach to treatment of advanced CRC in the near future. This review summarizes currently available data to select treatment strategies in patients with advanced CRC.",
keywords = "Biomarker, BRAF, Colorectal cancer (CRC), RAS",
author = "Thomas Semrad and Edward Kim",
year = "2016",
month = "4",
day = "1",
doi = "10.3978/j.issn.2078-6891.2015.094",
language = "English (US)",
volume = "7",
pages = "S11--S20",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - Molecular testing to optimize therapeutic decision making in advanced colorectal cancer

AU - Semrad, Thomas

AU - Kim, Edward

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Colorectal cancer (CRC) is a leading cause of cancer death in the United States. In recent years, therapeutic advances have prolonged the survival of patients with advanced disease. Along with the addition of new treatments, an increasing body of literature explores the potential benefit of using molecular testing to define tumor, circulating, or host biomarkers of benefit to specific treatment strategies. At present, testing for specific mutations in exons 2, 3, and 4 of KRAS and NRAS has become accepted practice to select patients for treatment with epidermal growth factor receptor (EGFR)-targeted agents. Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. Nonetheless, molecular markers to predict response and toxicity of cytotoxic therapy are evolving. While the development of selection biomarkers for antiangiogenic treatments has not proved fruitful to date, improved development strategies and novel targeted agents are anticipated to revolutionize the approach to treatment of advanced CRC in the near future. This review summarizes currently available data to select treatment strategies in patients with advanced CRC.

AB - Colorectal cancer (CRC) is a leading cause of cancer death in the United States. In recent years, therapeutic advances have prolonged the survival of patients with advanced disease. Along with the addition of new treatments, an increasing body of literature explores the potential benefit of using molecular testing to define tumor, circulating, or host biomarkers of benefit to specific treatment strategies. At present, testing for specific mutations in exons 2, 3, and 4 of KRAS and NRAS has become accepted practice to select patients for treatment with epidermal growth factor receptor (EGFR)-targeted agents. Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. Nonetheless, molecular markers to predict response and toxicity of cytotoxic therapy are evolving. While the development of selection biomarkers for antiangiogenic treatments has not proved fruitful to date, improved development strategies and novel targeted agents are anticipated to revolutionize the approach to treatment of advanced CRC in the near future. This review summarizes currently available data to select treatment strategies in patients with advanced CRC.

KW - Biomarker

KW - BRAF

KW - Colorectal cancer (CRC)

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=84995776174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995776174&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2015.094

DO - 10.3978/j.issn.2078-6891.2015.094

M3 - Review article

AN - SCOPUS:84995776174

VL - 7

SP - S11-S20

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

ER -